|
Jan 1
|
Exploring 3 Prominent High Growth Tech Stocks In The United States
|
|
Dec 30
|
Halozyme Announces Takeda Received Regulatory Approval for HYQVIA® 10% Subcutaneous Injection Set with ENHANZE® in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
|
|
Dec 30
|
Halozyme Announces argenx's VYDURA with ENHANZE® was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy
|
|
Dec 30
|
Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig™ with ENHANZE® for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo® (nivolumab) Indications
|
|
Oct 14
|
Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options
|
|
Oct 3
|
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE®
|
|
Oct 2
|
High Growth Tech Stocks In The United States To Watch
|
|
Sep 16
|
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
|
|
Sep 13
|
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
|
|
Sep 13
|
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
|
|
Sep 10
|
Q1 2025 Avid Bioservices Inc Earnings Call
|
|
Jul 30
|
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
|
Jul 29
|
5 Biotech Stocks to Bet On Bright Industry Prospects
|
|
Jul 26
|
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
|
|
Jul 23
|
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
|
|
Jul 23
|
Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy
|
|
Jul 23
|
Halozyme to Report Second Quarter 2024 Financial and Operating Results
|
|
Jun 25
|
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis
|
|
Jun 24
|
Halozyme Therapeutics (NASDAQ:HALO) shareholder returns have been stellar, earning 193% in 5 years
|
|
Jun 21
|
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy
|